New antibody therapy targets hard-to-treat lymphomas in early trial
NCT ID NCT04594642
First seen Nov 01, 2025 · Last updated May 25, 2026 · Updated 24 times
Summary
This early-phase study tests a new drug called AZD0486 in about 227 people with B-cell non-Hodgkin lymphoma, including types like diffuse large B-cell and follicular lymphoma. The drug is a special antibody that helps the immune system attack cancer cells. The main goals are to check safety, find the right dose, and see if it shrinks tumors. Participants must have already tried at least two other treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
RECRUITINGTampa, Florida, 33612, United States
-
Research Site
RECRUITINGLouisville, Kentucky, 40207, United States
-
Research Site
RECRUITINGNew Brunswick, New Jersey, 08901, United States
-
Research Site
RECRUITINGCharlotte, North Carolina, 28204, United States
-
Research Site
RECRUITINGColumbus, Ohio, 43210, United States
-
Research Site
WITHDRAWNPortland, Oregon, 97239, United States
-
Research Site
RECRUITINGPittsburgh, Pennsylvania, 15237, United States
-
Research Site
RECRUITINGAustin, Texas, 78704, United States
-
Research Site
RECRUITINGHouston, Texas, 77030, United States
-
Research Site
RECRUITINGMilwaukee, Wisconsin, 53226, United States
-
Research Site
WITHDRAWNBedford Park, 5042, Australia
-
Research Site
RECRUITINGHeidelberg, 3084, Australia
-
Research Site
RECRUITINGHobart, 7000, Australia
-
Research Site
RECRUITINGMelbourne, 3004, Australia
-
Research Site
RECRUITINGChūōku, 104-0045, Japan
-
Research Site
RECRUITINGKōtoku, 135-8550, Japan
-
Research Site
RECRUITINGNagoya, 460-0001, Japan
-
Research Site
RECRUITINGYamagata, 990-9585, Japan
-
Research Site
RECRUITINGSeoul, 03080, South Korea
-
Research Site
RECRUITINGSeoul, 05505, South Korea
-
Research Site
RECRUITINGSeoul, 06351, South Korea
-
Research Site
RECRUITINGSeoul, 06591, South Korea
-
Research Site
RECRUITINGSeoul, 120-752, South Korea
-
Research Site
RECRUITINGKaohsiung City, 833401, Taiwan
-
Research Site
RECRUITINGKweishan, 333, Taiwan
-
Research Site
RECRUITINGTainan, 704, Taiwan
-
Research Site
RECRUITINGTaipei, 10002, Taiwan
Conditions
Explore the condition pages connected to this study.